Papaverine

Papaverine – the combined anti-hypertensive and spasmolytic drug with analgeziruyushchy action.

Pharmacological action

Active agent of the Papaverine has anti-hypertensive, analgeziruyushchy and anticonvulsant effect.

Use of the Papaverine promotes decrease in a tone of unstriated muscles of internals of an urinary, respiratory, reproductive system and vessels, an arteriectasia and increase in a blood-groove.

In addition, Papaverin according to the instruction has hypotensive effect. In high doses active component of drug renders sedation, slows down endocardiac conductivity, and also promotes decrease in excitability of a cardiac muscle. In average therapeutic doses drug has slight effect on the central nervous system.

Safety and efficiency of use of the Papaverine at pregnancy and in the period of a lactation is not studied.

Release form

The papaverine is released in several dosage forms:

• Solution for injections (pricks), in ampoules on 2 ml containing 20 mg of active agent;
• The rectal candles containing 20 mg of active agent;
• The tablets containing 40 mg of active agent;
• The tablets for children containing 10 mg of active agent.

Indications to use of the Papaverine

According to the instruction the Papaverine is applied at spasms of unstriated muscles:

• Peripheral vessels – at an endarteritis;
• Bronchial tubes – at a bronchospasm;
• Brain vessels;
• Abdominal organs – at renal gripes, a pylorospasm, cholecystitis, a spastic colitis;
• Hearts – at stenocardia;

As supportive application use of the Papaverine is shown for premedication.

Contraindications to use of the Papaverine

According to the instruction it is contraindicated to apply the Papaverine at advanced age, to children up to 6 months, and also at:

• To AV blockade;
• Heavy liver failure;
• To glaucoma;
• Hypersensitivity to Papaverine components.

According to indications the Papaverine is applied with care:

• At a chronic renal failure;
• At a hypothyroidism;
• At supraventricular tachycardia;
• After a craniocereberal injury;
• At insufficiency of function of adrenal glands;
• In depressed cases;
• At a prostate hyperplasia.

Use of the Papaverine at pregnancy is possible only on doctor's orders.

During treatment by the Papaverine it is necessary to exclude alcohol intake.

Papaverine route of administration

According to indications the Papaverine in the form of tablets is accepted inside to four times a day. The adult single dose makes 40-60 mg of drug. The single dose for children depends on age:

• From 6 months to 2 years – on 5 mg;
• 3-4 years – from 5 to 10 mg;
• 5-6 years – 10 mg;
• 7-9 years – from 10 to 15 mg;
• 10-14 years – from 15 to 20 mg.

Solution for injections is entered subcutaneously and intramusculary by no more than 4 times a day on 1-2 ml. Intravenous administration is possible only slowly and under medical control, at the same time 20 mg of the Papaverine dissolve previously 0,9% of NaCl solution in 10-20 ml.

Use of the Papaverine in the form of candles, is admissible only the adult, on 20-40 mg to three times a day.

The dosage and duration of use of the Papaverine at pregnancy is defined individually by the doctor.

At overdose the Papaverine according to the instruction can cause drowsiness, a lowering of arterial pressure, weakness and a diplopia.

Strengthening of anticholinergic effects at simultaneous use of the Papaverine with anticholinergics is possible.

Description of side effects of the Papaverine

According to the description of the Papaverine and responses, at use of drug development is possible:

• Nausea;
• Drowsiness;
• Eosinophilias;
• Arterial hypotension;
• Allergic reactions;
• Ventricular premature ventricular contraction;
• Zaporov;
• The increased perspiration;
• Increases in activity of hepatic transaminases;
• AV blockade.

According to the instruction the Papaverine at bystry intravenous administration or at use in high doses can lead to development of disturbances of a cordial rhythm.

Storage conditions

The papaverine belongs to spasmolytic drugs of a prescription issue. A period of storage of tablets – 5 years, solution for injections – 24 months.